News

Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.

In part 2 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses what industry should be keeping top of mind when it comes to designing and executing pain clinical studies.

mRNA-1283 was found to elicit a higher immune response against SARS-CoV-2 than Moderna's licensed COVID-19 vaccine, mRNA-1273.

In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.

Combination demonstrated a favorable trend toward overall survival in non-small cell lung cancer patients.

Because of drastic changes in the clinical trial space, there is a need for advancing and streamlining design through risk-based methodologies and innovations.

Odronextamab is being evaluated for the treatment of relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma following two or more prior lines of systemic therapy.

Systematic review of 127 recent platform trials showed insufficient reporting of important trial information.

Amplifying the size and diversity of participant pools in clinical trials enhances statistical power and increases the generalizability of study findings.

Despite improvements, results from the study of SLS-005 (IV trehalose), a low molecular weight disaccharide, did not meet statistical significance.

New and renewed approaches to improve chances of success in developing non-addictive drugs for chronic pain.

Opdivo plus Yervoy was found to produce a statistically significant and clinically meaningful overall survival improvement compared with sorafenib or lenvatinib in patients with advanced hepatocellular carcinoma.

Results of cross-sectional study of 50 discharge summaries suggest a large language model can be used to increase their understandability.

Analysis of trial results show Imfinzi and Lynparza displayed a strong clinical benefit and more than doubled median duration of response vs. chemotherapy.

Pivotal Phase III Study 302 trial data show an objective response rate of 36.2% based on an independent review committee assessment in the treatment of relapsed/refractory cutaneous T-cell lymphoma.

In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.

Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients based on results from the pivotal Phase III KarMMa-3 study.

In light of scant published data from sponsors and contract research organizations on site activation and recruitment challenges following the COVID-19 pandemic, the primary objective of this research is to revisit the results of recruitment and retention tactics in studies conducted in 2012 and 2019.

Jemperli plus chemotherapy with or without adding maintenance treatment with Zejula produced a statistically significant overall survival and progression-free survival benefit in patients with primary advanced or recurrent endometrial cancer.

Keytruda plus chemoradiotherapy found to significantly improve overall survival in patients newly diagnosed with high-risk locally advanced cervical cancer.

Cross-sectional study of recent FDA drug approvals evaluated how closely they were aligned with US and global burden of disease.

THARROS trial investigators seek to provide first-of-its-kind evidence supporting a strategy of comprehensive cardiopulmonary risk reduction with a triple therapy in patients with chronic obstructive pulmonary disease.

Collaboration brings Flatiron’s oncology-specific decision support platform to oncology care clinicians at MUSC Hollings Cancer Center.

Although there are much larger problems in clinical research, storing obsolete study records is a totally unnecessary cost.

Clinical trials planned for the fourth quarter of 2024 will evaluate a new multi-valent vaccine to protect against multiple types of human papillomavirus, and to analyze the efficacy and safety of a single-dose of Gardasil 9.

Effective immediately, the acquisition strengthens both organizations’ abilities to recruit and retain diverse populations for clinical trials.

Transparent and detailed communication throughout the research process is key for effectively recruiting and retaining patients for clinical trials.

Industry leaders discuss how technology can help companies adapt to the regulatory changes and accomplish their DE&I goals.

Adcetris (brentuximab vedotin) plus lenalidomide and rituximab produced statistically significant and clinically meaningful improvements in overall survival in patients with relapsed or refractory diffuse large B-cell lymphoma.

Exploring a human-centered, holistic approach for equitable trial outcomes.